Susceptibility of Developing Renal and Lung Cancer in Polycystic Kidney Disease Patients: An Evidence in Reaching Consensus

Table 2

SIR for cancers in PKD patients.

Site of cancers	Total			Male			Female
	Observed	Expected	SIR (95% CI)	Observed	Expected	SIR (95% CI)	Observed	Expected	SIR (95% CI)
All cancers	82	68.53	1.20 (0.95–1.49)	59	46.56	1.27 (0.96–1.63)	23	21.97	1.05 (0.66–1.57)
Head and neck	5	5.45	0.92 (0.30–2.14)	4	4.88	0.82 (0.22–2.10)	1	0.57	1.76 (0.02–9.77)
Digestive	33	27.84	1.19 (0.82–1.67)	27	20.09	1.34 (0.89–1.96)	6	7.75	0.77 (0.28–1.69)
Esophagus	1	1.52	0.66 (0.01–3.67)	0	1.42	—	1	0.09	10.83 (0.14–60.24)
Stomach	4	3.64	1.10 (0.30–2.81)	4	2.68	1.49 (0.40–3.82)	0	0.96	—
Colon & rectum	11	10.34	1.06 (0.53–1.90)	8	6.96	1.15 (0.50–2.27)	3	3.38	0.89 (0.18–2.59)
Biliary tract	15	10.57	1.42 (0.79–2.34)	13	7.86	1.65 (0.88–2.83)	2	2.72	0.74 (0.08–2.66)
Pancreas	1	1.37	0.73 (0.01–4.07)	1	0.91	1.10 (0.01–6.10)	0	0.46	—
Lung & mediastinum	15	8.59	1.75 (0.98–2.88)	9	6.48	1.39 (0.63–2.64)	6	2.12	2.83 (1.03–6.16)
Bone & soft tissue	0	1.70	—	0	1.16	—	0	0.54	—
Skin	1	2.15	0.47 (0.01–2.59)	1	1.33	0.75 (0.01–4.17)	0	0.81	—
Breast	2	3.79	0.53 (0.06–1.91)	0	0.04	0.00 (88.32)	2	3.75	0.53 (0.06–1.93)
Genitourinary	18	11.37	1.58 (0.94–2.50)	13	7.6	1.71 (0.91–2.93)	5	3.77	1.32 (0.43–3.09)
Cervix	0	1.25	—	0	0	—	0	1.25	—
Uterus	1	0.66	1.51 (0.02–8.43)	0	0	—	1	0.66	1.51 (0.02–8.43)
Ovary	0	0.50	—	0	0	—	0	0.5	—
Prostate	6	4.51	1.33 (0.49–2.90)	6	4.51	1.33 (0.49–2.90)	0	0	—
Bladder	3	2.08	1.44 (0.29–4.22)	3	1.64	1.83 (0.37–5.34)	0	0.44	—
Kidney	8	2.15	3.72 (1.60–7.33)	4	1.31	3.04 (0.82–7.79)	4	0.84	4.78 (1.29–12.25)
CNS	0	0.41	—	0	0.27	—	0	0.14	—
Thyroid	2	0.88	2.28 (0.26–8.25)	0	0.27	—	2	0.6	3.31 (0.37–11.97)
Hematologic malignancies	4	5.47	0.73 (0.20–1.87)	3	3.68	0.82 (0.16–2.38)	1	1.79	0.56 (0.01–3.10)
All others	2	0.89	2.25 (0.25–8.12)	2	0.76	2.64 (0.30–9.54)	0	0.13	—

SIR, Standardized Incidence Ratio; PKD, Polycystic Kidney Disease; CI, Confidence Interval; CNS Central Nervous System. . Bold values have symbol indicating significant .